Brain-Heart Interactions in Traumatic Brain Injury

Ayman El-Menyar1, Abhishek Goyal, Rifat Latifi

  • 1From the *Department of Surgery, Clinical Research, Westchester Medical Center, Valhalla, NY; †Clinical Medicine, Weill Cornell Medical College, Doha, Qatar; ‡Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY; §Department of Surgery, New York Medical College/Westchester Medical Center, Valhalla, NY; and ¶Department of Surgery, Trauma & Vascular Surgery, Hamad General Hospital, Qatar.

Cardiology in Review
|October 7, 2017
PubMed

Insights

Traumatic brain injury (TBI) can cause heart problems. Beta-blockers show promise in reducing TBI mortality, but further research is needed to optimize their use.

Area of Science:

  • Neuroscience
  • Cardiology
  • Trauma Surgery

Background:

  • Cardiovascular manifestations are known in nontraumatic head disorders and have been reported in traumatic brain injury (TBI).
  • The underlying mechanisms and clinical outcome impact of these cardiovascular manifestations in TBI are not well understood.
  • The neurocardiac axis and neurogenic stunned myocardium offer potential explanations for the brain-heart interaction in TBI.

Purpose of the Study:

  • To explore the mechanisms and clinical implications of cardiovascular manifestations in TBI.
  • To review the potential role of beta-adrenergic blockers in managing TBI-related cardiovascular complications and mortality.
  • To identify key questions for future randomized-controlled trials investigating beta-blocker therapy in TBI patients.

Main Methods:

  • Review of existing literature on TBI and associated cardiovascular manifestations.
  • Analysis of observational retrospective studies on the use of beta-adrenergic blockers in TBI.
  • Identification of knowledge gaps and areas for future clinical research.

Main Results:

  • Observational studies suggest beta-adrenergic blockers may reduce TBI-related mortality.
  • The neurocardiac axis and neurogenic stunned myocardium provide a framework for understanding brain-heart interactions in TBI.
  • Significant questions remain regarding optimal beta-blocker selection, dosage, timing, and duration in TBI management.

Conclusions:

  • Understanding the brain-heart link in TBI is crucial for improved patient outcomes.
  • Beta-blocker therapy presents a promising avenue for reducing TBI mortality, warranting further investigation.
  • Randomized-controlled trials are essential to establish evidence-based guidelines for beta-blocker use in TBI, considering factors like patient selection and hemodynamic management.

Related Concept Videos